Results 81 to 90 of about 56,276 (247)

Exposure‐Response Relationships for Axatilimab in Patients with Chronic Graft‐Versus‐Host Disease

Clinical Pharmacology &Therapeutics, EarlyView.
Axatilimab, a high‐affinity humanized monoclonal antibody that targets colony‐stimulating factor 1 receptor, is approved for the treatment of chronic graft‐versus‐host disease (cGVHD). Here, we describe the exposure‐response relationships for efficacy and safety in patients with cGVHD who received axatilimab.
Yan‐ou Yang, Alina Volkova, Victor Sokolov, Xing Liu, Cristina Leon, Yuri Kosinsky, Jennifer Sheng, Xuejun Chen   +7 more
wiley   +1 more source

Biomarkers of lung congestion and injury in acute heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi, Gabriele Novello, Francesca Bursi, Anna Caretti, Noemi Furlotti, Ross Arena, Paola Argiento, Julio Núñez, Antoni Bayes‐Genis, Marco Metra   +9 more
wiley   +1 more source

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

European Journal of Heart Failure, EarlyView.
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...
Alessandra Ghigo, Pietro Ameri, Aarti Asnani, Edoardo Bertero, Rudolf A. de Boer, Dimitrios Farmakis, Arantxa González, Stephane Heymans, Borja Ibáñez, Teresa López‐Fernández, Alexander R. Lyon, Piero Pollesello, Amina Rakisheva, Konstantinos Stellos, Katrin Streckfuss‐Bömeke, Carlo Gabriele Tocchetti, Thomas Thum, Peter van der Meer, Eva Van Rooij, Piotr Ponikowski, Marco Metra, Giuseppe Rosano, Sophie Van Linthout   +22 more
wiley   +1 more source

Single‐cell sequencing reveals the role of IL‐33+ endothelial subsets in promoting early gastric cancer progression

iMeta, EarlyView.
A single‐cell atlas was established to reveal the molecular characteristics of early gastric cancer (EGC). In combination with organoids, animal models, and clinical samples, it was found that subpopulations such as pit mucous‐like cell (PMC‐like), proliferating cell (PC), CH25H+ CD4+ T cell, IL‐33+ endothelial cell, and ADAMTSL2+ endothelial cell are ...
Li Zhou, Mei Yang, Chao Deng, Manqiu Hu, Suhua Wu, Kewen Lai, Lili Zhang, Zhiji Chen, Qin Tang, Qingliang Wang, Lu Chen, Runmin Zha, Yuanyuan Chen, Yibo Tan, Song He, Zhihang Zhou   +15 more
wiley   +1 more source

Racing toward the future of chronic hepatitis B management: Achieving functional cure and enhancing hepatocellular carcinoma surveillance through precision medicine

Interdisciplinary Medicine, EarlyView.
Novel biomarker emergence plays a critical role in improving CHB management. Advances in sensitive detection methods, AI, and large‐scale data platforms have independently contributed to biomarkers while driving the development of multi‐omics approaches.
Yaru Shi, Rong Fan
wiley   +1 more source

Patient‐derived xenograft models in pan‐cancer: From bench to clinic

Interdisciplinary Medicine, EarlyView.
Abstract Patient‐derived xenograft (PDX) models provide a robust preclinical platform that preserves the genetic and phenotypic heterogeneity of patient tumors while mirroring their tumor genetic characteristics, which retain malignant cells and the tumor pathological structure, making them valuable for studying tumor progression and developing ...
Jiatong Li, Ao Gu, Nannan Tang, Gokhan Zengin, Meng‐Yao Li, Yingbin Liu   +5 more
wiley   +1 more source

Population Pharmacokinetics and Exposure–Response Relationships of Etrolizumab in Patients with Moderately‐to‐Severely Active Crohn's Disease

The Journal of Clinical Pharmacology, EarlyView.
Abstract This study aimed to characterize the pharmacokinetics (PK) of etrolizumab, an IgG1‐humanized monoclonal anti‐β7 integrin antibody, and assess its exposure–response (ER) relationship for key clinical outcomes in patients with moderately‐to‐severely active Crohn's disease.
Anita Moein, Jakob Ribbing, Moustafa M. A. Ibrahim, Wenhui Zhang, Nastya Kassir   +4 more
wiley   +1 more source

Development of a step‐gradient simulated moving bed process for the polishing of monoclonal antibodies with anion exchange chromatography

Journal of Chemical Technology &Biotechnology, EarlyView.
Abstract BACKGROUND In recent years, biopharmaceutical applications in medicine have seen explosive growth and the need for efficient, rapid and inexpensive purification of these targets is the topic of tremendous research and development. The need to improve process efficiency has been an active area of investigation due to the tremendous potential ...
Yasmina MJ Harsy, Jonas Wege, Anthony Grabski, Romain Dabre, Egbert Müller, Carsten‐René Arlt   +5 more
wiley   +1 more source

Successful Treatment of Spesolimab in a Haemodialysis Patient With Acutely Flaring Generalised Pustular Psoriasis

JEADV Clinical Practice, EarlyView.
Capsule Summary Generalised pustular psoriasis is one of the severe dermatological disorders. The use of biologics in psoriatic patients with end‐stage renal disease is rare, and the safety information on biologics treatment in such patients is limited.
Yasuyuki Fujita, Sota Itamoto, Akihiro Orita, Kunihiro Kawashima, Satoko Shimizu   +4 more
wiley   +1 more source

Recent Advancements in the Treatment of Age‐Related Macular Degeneration

Med Research, EarlyView.
ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu, Danyang Lv, Junran Sun, Huixun Jia, Fang Zheng, Felipe Pereira, Siddharth Narendran, Zhenyu Dong, Haiyun Liu, Shunxiang Gao, Peirong Huang   +10 more
wiley   +1 more source